Clearside Biomedical announces ARCATUS approved in Australia, Singapore

Clearside Biomedical (CLSD) announced that Arctic Vision’s new drug applications for ARCATUS have been approved by the Therapeutic Goods Administration of Australia and the Health Sciences Authority in Singapore for the treatment of uveitic macular edema, UME. George Lasezkay, PharmD, JD, President and Chief Executive Officer of Clearside, commented, “We congratulate our partner, Arctic Vision, for the outstanding progress advancing our product in the Asia-Pacific region. These global regulatory approvals confirm that our innovative SCS delivery platform enables the treatment of patients with sight-threatening eye diseases. We expect that retinal specialists across the world will use this in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of potential therapies.”